Announcements
OBI announces termination of BCVax, OBI-866, and OBI-999
1.Date of occurrence of the event:2023/12/20 2.Company name:OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: NA 5.Cause of occurrence: After prudent …
Announcement of resignation of the Chairperson
1.Date of the board of directors resolution or date of occurrence of the change:2023/12/20 2.Position (Please enter chairperson or president/general manager): Chairperson 3.Name of the previous position holder: Yun Yen …
OBI licensed the worldwide therapeutic rights of OBI-858 to OBIGEN
1.Date of occurrence of the event:2023/12/20 2.Counterparty to the contract or commitment: OBIGEN Pharma, Inc. 3.Relationship with the Company: OBIGEN is a subsidiary held 52% of voting shares by the …
Announcement on behalf of subsidiary, OBIGEN, that the Company’s board appointed internal audit officer
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development …
OBI has filed the application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to US FDA
1.Date of occurrence of the event:2023/12/01 2.New drug name or code:OBI-992 TROP2 ADC 3.Indication: OBI-992 is an Antibody Drug Conjugate (ADC) for cancer treatment that is based on TROP2 to …
OBI is invited to attend the investor conference hosted by MasterLink Securities and declare the development of all its products and future plan
1.Date of institutional investor conference: 2023/12/06 2.Time of institutional investor conference: 14:30 3.Location of institutional investor conference: Taipei Bioinnovation Park 1F Conference Room (No. 508, Section 7, Zhongxiao East Road, …
The change of the Company’s business address was approved by the Board of Directors
1.Date of occurrence of the event:2023/11/06 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office 4.Reciprocal shareholding ratios: NA 5.Cause of occurrence: …
Announcement of change of internal audit officer
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development …
Announcement of change of financial officer
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development …
Announcement of the Consolidated Financial Statements for the third quarter of 2023 were approved by the Board of Directors
1.Date of the board of directors submitted or approved:2023/11/06 2.Date of the audit committee approved:2023/11/03 3.Start and end dates of financial reports or unaudited financial information of the reporting period …